Spots Global Cancer Trial Database for A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"
Official Title: A Postmarketing Observational Cohort Study to Evaluate Effectiveness and Safety of Ponatinib (Iclusig®) in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"
Study ID: NCT03515785
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the effectiveness and safety of ponatinib (Iclusig®) in patients with BCR-ABL positive acute lymphoblastic leukemia (ALL) in standard clinical practice in Europe.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ihbt/Úhkt, Praha, , Czechia
University Hospital Amiens, Amiens, , France
University Hospital Angers, Angers, , France
University Hospital Bordeaux, Bordeaux, , France
University Hospital Grenoble, Grenoble, , France
University Hospital Lyon, Lyon, , France
University Cancer Institute Oncopole, Toulouse, , France
University Hospital Halle/Saale, Halle/Saale, , Germany
University Hospital Munich, Munich, , Germany
University Hospital Rostock, Rostock, , Germany
Contact Details
Name: Dieter Hoelzer, Prof. Dr. med.
Affiliation: Oncologikum Frankfurt
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
